The heartbreaking story of Evan Armit, a promising young hockey player from Dryden, Ontario, underscores the critical shortcomings within Canada’s healthcare system, particularly in accessing life-saving cancer treatments. After being diagnosed with aggressive melanoma, Evan’s family faced insurmountable bureaucratic hurdles in their desperate quest for a cutting-edge therapy. His untimely death, just days after a potentially life-saving treatment was approved in Canada, raises urgent questions about the accessibility of innovative medical care for patients in need.
A Call for Help in Desperation
On May 9, 2025, Brian Armit was in Winnipeg, where he and his family were attending a Jets playoff game, when he received a phone call that would become a pivotal moment in their lives. The call came from Ontario Premier Doug Ford, responding to Brian’s plea for assistance as his son Evan, just 22 years old, struggled against a terminal cancer diagnosis. The family had been hopeful that a novel treatment known as tumour-infiltrating lymphocyte (TIL) therapy could provide a lifeline, but regulatory delays in Canada had left them in a precarious situation.
Evan’s family had submitted a request to the Ontario Health Insurance Plan (OHIP) for out-of-country coverage to facilitate the expensive treatment at a Boston hospital, estimated to cost between $750,000 and $1 million. Their application was denied twice, prompting Brian to reach out directly to the Premier. While Ford expressed genuine concern during their conversation, the administrative response from the provincial health authorities was disheartening. Instead of immediate aid, they were advised to follow a lengthy appeals process.
The Appeals Process and a Tragic Outcome
The family’s hopes were further dashed when, on August 28, 2025—just four days after Evan’s death—the Ontario Health Services Appeal and Review Board issued a final ruling denying their appeal for funding. The timing was particularly cruel, as Health Canada had just approved TIL therapy, which could have made a significant difference in Evan’s battle against melanoma. His treating oncologist, Dr. Joseph Del Paggio, lamented the extended delays and bureaucratic hurdles that obstructed timely access to the treatment. “Evan deserved this option,” he stated, emphasising the frustration felt by medical professionals who believed in the scientific validity of the therapy.
Evan’s case is emblematic of the broader issues plaguing cancer care in Canada, where there exists an average two-and-a-half-year gap between the approval of new medications in the United States and their availability through public funding in Canada. Although there are mechanisms like Health Canada’s Special Access Program (SAP) designed to expedite access to unapproved therapies, TIL therapy’s unique nature complicates its inclusion.
The Complicated Nature of Innovative Therapies
TIL therapy involves extracting immune cells from a patient’s tumour, growing them in a lab, and then reinfusing them to combat cancer. This process requires a nuanced understanding of how such personalised treatments should be classified within the healthcare system. According to Mina Tadrous, a pharmaceutical policy expert at the University of Toronto, the distinction between considering TIL therapy as a drug versus a medical procedure remains contentious. This classification affects funding decisions and contributes to delays in access.
In Evan’s case, the appeal panel determined that OHIP’s out-of-country prior approval programme was inappropriate for therapies awaiting public funding review. Had TIL therapy been recognised as a procedure akin to stem-cell transplants, the outcome might have been different. Instead, the bureaucratic machinery continued to operate without urgency, while Evan’s health deteriorated.
A Call for Change
The Armit family is now determined to use their story as a catalyst for change within Ontario’s healthcare landscape. They advocate for a more flexible approach to funding life-saving treatments, particularly when time is of the essence. Evan’s cancer journey began in the summer of 2024, shortly after he returned from a dream trip to Europe. The first signs of melanoma—a small black lesion on his heel—quickly escalated into a battle against a disease that would spread aggressively.
Despite the overwhelming odds, Evan remained remarkably positive throughout his ordeal, a testament to his character and resilience. His family remembers him as a vibrant young man, beloved for his kindness and enthusiasm for life. His eulogy celebrated not only his athletic achievements but also his deep connections with family and friends, underscoring the profound loss felt by all who knew him.
Why it Matters
Evan Armit’s story is a stark reminder of the urgent need for reform in the Canadian healthcare system, particularly regarding access to innovative cancer treatments. As families grapple with the emotional and financial toll of battling life-threatening illnesses, the systemic barriers that delay access to lifesaving therapies must be scrutinised and addressed. The Armit family’s experience highlights the necessity for a healthcare system that prioritises patient needs and facilitates timely access to groundbreaking treatments, ensuring that no one has to endure what Evan did. The time for change is now—before more lives are lost to the inefficiencies of a system that should be protecting its most vulnerable citizens.
